Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesions which are not being detected in early disease status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting. There are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and periampullary cancer and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC and periampullary Cancer. This randomized controlled trial compares neoadjuvant chemotherapy followed by surgery versus upfront surgery for patients with clearly resectable pancreatic head cancer and periampullary cancer. The study aims to determine if neoadjuvant chemotherapy improves overall survival compared to immediate surgery followed by adjuvant chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie lub cytologicznie rak głowy trzustki lub rak okolic brodawki dwunastnicznej
- •Nowotwór w stadium operacyjnym bez rozrostu na główne naczynia krwionośne
- •Brak widocznych przerzutów (rozsiania) nowotworu
- •Dobry stan zdrowotny pacjenta (ECOG 0-1)
- •Prawidłowe funkcjonowanie wątroby, nerek i szpiku kostnego
- •Zgoda pacjenta na udział w badaniu
- •Brak wcześniejszej operacji trzustki lub chemioterapii raka trzustki
- •Liczba leukocytów, płytek krwi i hemoglobina w wymaganym zakresie
✗ Disqualifies
- •Nowotwór w stadium granicznym lub zaawansowanym
- •Rak ciała lub ogona trzustki
- •Przerzuty do odległych narządów
- •Wcześniejsza chemioterapia, operacja lub radioterapia raka trzustki
- •Poważne choroby uniemożliwiające operację lub chemioterapię
- •Ciąża lub karmienie piersią
- •Inne nowotwory złośliwe w ostatnich 5 latach
- •Poważna operacja lub uraz w ciągu ostatnich 28 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Liver and GIT hospital , Minia University
Minya, Egypt
Trial contact
Saleh K Saleh, MD
Rabeh K Saleh, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.